The proof for new oral anticoagulants: clinical trial evidence.

ABSTRACT: INTRODUCTION: Patients undergoing elective total hip or total knee replacement surgery are at increased risk of venous thromboembolism in the post-operative period and are recommended to receive thromboprophylaxis for 10-35 days. Although several thromboprophylactic agents are available, these are associated with well-recognized limitations. For the low molecular weight heparins (LMWHs) such as enoxaparin, these limitations include parenteral administration, indirect mode of action, inability to inhibit clot-bound thrombin and association with complications such as heparin-induced thrombocytopenia. These limitations make post-operative thromboprophylaxis challenging. Several new oral anticoagulants are in the advanced stages of clinical development. These agents have been designed to targe

SUBMITTER: Huisman MV 

PROVIDER: S-EPMC3150805 | biostudies-literature | 2011 Jul

REPOSITORIES: biostudies-literature